

PRIVATE EQUITY RISING STAR

Isabel Berger GIBSON, DUNN & CRUTCHER

Year of birth: 1983

Position: partner, since February 2022

**Key clients: KKR, Blackfin Capital Partners,
TowerBrook Capital Partners**



Isabel Berger, who was made partner at Gibson Dunn last year, believes that private equity has moved away from the “Barbarians at the Gate” image”. She adds that seeing the industry become more “diverse, international and... often highly sector focused” is something she observed whilst being on secondment at KKR.

Her relationship with the firm led to her advising Gamma Biosciences, a life sciences platform formed by KKR, on the sale of its operating company Astrea Bioseparations to Swedish listed company Biotage earlier this year.

Her strength on cross-border transactions is doubtless helped by her fluency in English and German—as well as

what the firm describes as her “cultural intelligence” which it says “has enabled her to build and maintain strong relationships with a global network of clients who trust her to advise on international transactions”. It also praises the fresh perspective she brings as a woman operating in a traditionally male-dominated industry.